Group | N | CD3+T cells (%) | CD3+CD4+T cells (%) | CD3+CD8+T cells (%) | Ratio of CD4+/CD8+ | CD4+/CD25+T cells (%) |
---|---|---|---|---|---|---|
DLBCL patients at baseline | 56 | 72.09 ± 3.16 | 32.31 ± 3.65 | 37.53 ± 6.46 | 0.85 ± 0.49 | 5.48 ± 4.96 |
DLBCL after three cycles of chemotherapy | 56 | 71.24 ± 6.2 | 34.09 ± 4.63 | 32.51 ± 5.25 | 1.06 ± 0.87 | 8.32 ± 3.54 |
Healthy controls | 26 | 72.90 ± 5.83 | 41.78 ± 4.23 | 28.51 ± 2.14 | 1.47 ± 0.27 | 3.68 ± 1.03 |